CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 17 enrolled
Drug / intervention
TH-1 Dendritic Cell Immunotherapybiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04552886
NCT04552886Phase 1Completed
CompareCT.gov

A Phase I Study of Th-1 Dendritic Cell Immunotherapy in Combination With Standard Chemoradiation for the Adjuvant Treatment of Adult Glioblastoma

The Cooper Health System·interventional·Posted Sep 17, 2020·Updated Jan 11, 2024

In Brief

A Phase 1 clinical trial evaluating TH-1 Dendritic Cell Immunotherapy for Glioblastoma. Completed, enrolled 17 participants across 2 sites.

Detailed Summary

Effective treatments are desperately needed for glioblastoma (GBM) patients. This phase I clinical trial assesses the safety of a novel personalized dendritic-cell vaccine administered to GBM patients shortly after completing standard-of-care treatments. Secondary outcomes will evaluate patient progression-free survival and overall survival.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma
CountriesUnited States
CollaboratorsBaylor College of Medicine, Philadelphia College of Osteopathic Medicine

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedSep 17, 2020
Enrollment StartOct 11, 2021
Primary CompletionDec 1, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5.8 years ago

Interventions

TH-1 Dendritic Cell Immunotherapybiological

Adult patients with histopathologically diagnosed glioblastoma will be eligible for this novel, personalized dendritic cell vaccine after completing standard of care chemoradiation.